Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $12.9 million.

  • Taysha Gene Therapies' Accumulated Expenses rose 40.45% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 40.45%. This contributed to the annual value of $12.9 million for FY2024, which is 4.71% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Accumulated Expenses stood at $12.9 million for FY2024, which was up 4.71% from $12.3 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Accumulated Expenses registered a high of $18.3 million during FY2022, and its lowest value of $12.3 million during FY2023.
  • For the 3-year period, Taysha Gene Therapies' Accumulated Expenses averaged around $14.5 million, with its median value being $12.9 million (2024).
  • Per our database at Business Quant, Taysha Gene Therapies' Accumulated Expenses plummeted by 32.83% in 2023 and then climbed by 4.71% in 2024.
  • Over the past 3 years, Taysha Gene Therapies' Accumulated Expenses (Yearly) stood at $18.3 million in 2022, then plummeted by 32.83% to $12.3 million in 2023, then grew by 4.71% to $12.9 million in 2024.